Menopause

01Pathophysiology

Menopause represents the permanent cessation of menstruation resulting from irreversible loss of ovarian follicular activity. Throughout a woman's reproductive life, the finite pool of primordial follicles undergoes continuous atresia. By the late 40s, the remaining follicle count drops below the threshold required to sustain regular ovulatory cycles.

As follicles decline, estradiol and inhibin B production fall. Since inhibin B is the primary negative feedback signal to FSH secretion from the anterior pituitary, its loss results in a compensatory and progressive rise in FSH. This is why FSH becomes the hallmark laboratory finding. The elevated FSH initially drives the remaining follicles into accelerated, irregular recruitment, which explains the erratic menstrual cycles seen during the perimenopause transition (cycles may shorten, then lengthen, then become anovulatory).

Once follicular reserves are fully exhausted, estradiol levels become chronically low. This estrogen withdrawal is directly responsible for the classic symptom profile:

Vasomotor symptoms (hot flashes, night sweats) arise because estrogen modulates the thermoregulatory center in the hypothalamus. Low estrogen narrows the thermoneutral zone, meaning even minor core temperature fluctuations trigger inappropriate heat-dissipation responses (peripheral vasodilation, sweating). This is the most commonly tested symptom.

Genitourinary syndrome of menopause (previously called vulvovaginal atrophy) occurs because the vaginal epithelium, urethra, and bladder trigone are estrogen-dependent tissues. Without estrogen, the vaginal mucosa thins, loses glycogen, and the pH rises (becoming more alkaline), predisposing to recurrent UTIs and dyspareunia. Unlike vasomotor symptoms, genitourinary symptoms do not improve with time and tend to worsen progressively.

Bone loss accelerates because estrogen normally suppresses osteoclast activity. The first 5-7 years after menopause see the most rapid decline in bone mineral density, placing postmenopausal women at elevated risk for osteoporosis and fracture.

The cardiovascular risk profile also shifts: estrogen has favorable effects on lipid metabolism (raising HDL, lowering LDL) and endothelial function. After menopause, LDL rises and HDL falls, contributing to the increased incidence of coronary artery disease in postmenopausal women.

02Classification and Clinical Manifestation

Clinical Manifestation

03Diagnostic Workup

In women older than 45 with classic symptoms and 12 months of amenorrhea, the diagnosis of menopause is entirely clinical. No laboratory testing is required. This is a frequently tested point: the exam will present a straightforward clinical picture and test whether you order unnecessary labs.

FSH measurement becomes the best initial test when the clinical picture is ambiguous. This includes women aged 40-45 with irregular cycles, women who have undergone hysterectomy (no menstrual history to reference), or women on hormonal contraception that masks menstrual patterns. A single elevated FSH can be misleading during perimenopause because levels fluctuate widely, so two measurements separated by 4-6 weeks are recommended to confirm.

TSH and beta-hCG are important rule-out tests. Hypothyroidism can mimic several menopausal symptoms (fatigue, menstrual irregularity, mood changes, weight gain), and pregnancy must always be excluded in any woman of reproductive potential presenting with amenorrhea, even if she is in her late 40s.

Anti-Mullerian hormone (AMH) reflects ovarian reserve and declines to undetectable levels at menopause. While increasingly used in fertility assessment, it is not routinely tested for menopause diagnosis. It is more relevant in evaluating premature ovarian insufficiency.

For premature ovarian insufficiency (menopause before 40), the workup is more extensive: karyotype (to detect Turner syndrome mosaicism such as 45,X), FMR1 premutation testing (fragile X carrier status), 21-hydroxylase antibodies (autoimmune adrenal insufficiency), and thyroid peroxidase antibodies should all be obtained.

A critical exam scenario: any postmenopausal bleeding requires endometrial evaluation regardless of how long the patient has been menopausal. The standard approach is transvaginal ultrasound first. If endometrial thickness is > 4 mm, endometrial biopsy follows. The concern is endometrial hyperplasia or carcinoma.

04Management and Treatment

Hormone replacement therapy (HRT) remains the most effective treatment for vasomotor symptoms. The fundamental principle for exam purposes: a woman with an intact uterus must receive a progestogen alongside estrogen to prevent unopposed estrogen stimulation of the endometrium, which leads to endometrial hyperplasia and increases the risk of endometrial carcinoma. A woman who has had a hysterectomy can safely receive estrogen-only therapy.

The recommended approach is to use the lowest effective dose for the shortest necessary duration. Current guidelines support initiating HRT in symptomatic women within 10 years of menopause onset or before age 60 (the "window of opportunity"). In this group, the benefits of symptom relief and bone protection outweigh the risks. Starting HRT in women over 60 or more than 10 years past menopause is associated with increased cardiovascular and thromboembolic risk and is generally not recommended.

Absolute contraindications to systemic HRT include: unexplained vaginal bleeding, active or recent breast cancer, active thromboembolic disease or history of DVT/PE, active liver disease, and known thrombophilia (e.g., Factor V Leiden). Coronary heart disease is also a contraindication to initiating HRT.

Transdermal estrogen (patches, gels) is preferred over oral formulations in women with elevated thrombotic risk, hypertriglyceridemia, or migraine with aura, because transdermal delivery bypasses hepatic first-pass metabolism and does not increase clotting factor production or triglyceride levels.

For isolated genitourinary symptoms (vaginal dryness, dyspareunia, recurrent UTIs without bothersome hot flashes), low-dose vaginal estrogen is the treatment of choice. Systemic absorption is minimal, and current evidence does not support the need for concomitant progestogen. This is a commonly tested distinction.

Non-hormonal alternatives are indicated when HRT is contraindicated or refused. Paroxetine 7.5 mg/day (low-dose, brand name Brisdelle) is the only FDA-approved non-hormonal medication for hot flashes. Venlafaxine and gabapentin are also effective. Paroxetine should be avoided in women taking tamoxifen because it inhibits CYP2D6, the enzyme required to convert tamoxifen to its active metabolite endoxifen.

For premature ovarian insufficiency, HRT is not optional but rather strongly recommended until at least the age of natural menopause (approximately 51 years) to mitigate the long-term consequences of prolonged estrogen deficiency: accelerated osteoporosis, increased cardiovascular mortality, and possible cognitive decline.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on menopause questions involves ordering unnecessary labs in a straightforward clinical scenario. When a 52-year-old woman presents with 12 months of amenorrhea and classic vasomotor symptoms, the answer is a clinical diagnosis. Choosing "check FSH" when no ambiguity exists is a trap.

The second major pitfall is forgetting to add progestogen in a woman with an intact uterus receiving estrogen therapy. Test-writers will present a patient on estrogen-only HRT who then develops abnormal uterine bleeding. The teaching point is unopposed estrogen and endometrial hyperplasia risk.

A third commonly tested concept: the exam presents a breast cancer survivor with debilitating hot flashes and asks for the next best step. HRT is contraindicated. The correct answer is a non-hormonal agent (paroxetine, venlafaxine, or gabapentin). However, if this patient is also taking tamoxifen, paroxetine is wrong due to CYP2D6 inhibition. Venlafaxine or gabapentin becomes the answer.

Watch for the vignette describing a postmenopausal woman with any vaginal bleeding, even spotting. This always demands endometrial evaluation (transvaginal ultrasound followed by biopsy if indicated). "Reassurance" or "observation" is never acceptable for postmenopausal bleeding.

Finally, premature ovarian insufficiency (before age 40) is treated differently from natural menopause: HRT is strongly indicated until the average age of natural menopause to prevent long-term sequelae. A young woman presenting with elevated FSH and amenorrhea should not simply be told she is "going through menopause early" without a thorough etiologic workup and initiation of hormone therapy.

The core competency being tested across menopause questions is the ability to match clinical context to the correct diagnostic and management pathway: clinical diagnosis when the picture is clear, targeted labs when it is not, appropriate HRT selection based on uterine status and contraindications, and recognition of red flags that demand further investigation.